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The electronic records of 398 patients with chronic spontaneous urticaria (CSU) who had had a serum basophil
histamine release assay (BHRA) performed as a marker of functional autoantibodies were audited. The BHRA was
positive in 105 patients (26.4%). Fifty eight were treated with ciclosporin because they were H1 anti-histamine
unresponsive. CSU patients with a positive BHRA were more likely to respond clinically (P<0.001) and to have raised
thyroid autoantibodies (P<0.02) than those with a negative BHRA. The BHRA offers a useful predictive biomarker for
a good response of H1 antihistamine-unresponsive CSU patients to ciclosporin.
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Functional factors including histamine-releasing auto-
antibodies have been identified by the BHRA in the sera
of 20–30% of patients with CSU [1-3]. CSU patients with
a positive BHRA also have a higher incidence of thyroid
antibodies than those without [4]. A double-blind pla-
cebo controlled study of ciclosporin for chronic idio-
pathic urticaria showed that more patients with a
positive BHRA responded to ciclosporin than those with
a negative BHRA [5] but this observation is not widely
known. If confirmed, the BHRA could be used as a bio-
marker to predict a good response to treatment with
ciclosporin and provide additional justification for using
this third-line immunosuppressive agent in CSU patients
with antihistamine-unresponsive disease.
The electronic case records of CSU patients attending
a specialist Urticaria Clinic at St John’s Institute of
Dermatology, London, who had a BHRA performed on
their sera by RefLab, Copenhagen (HR-Urtikaria TestW)
[6] between November 2004 and March 2011 were
reviewed retrospectively by one of the authors to identify
those with H1 antihistamine-unresponsive CSU treated
with ciclosporin and their response to it. None of the
patients had an autologous serum skin test. The usual* Correspondence: clive.grattan@nnuh.nhs.uk
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reproduction in any medium, provided the orstarting dose of ciclosporin was 4 mg/kg/d and the usual
duration of treatment was between 3 and 4 months.
Patients with other patterns of chronic urticaria includ-
ing inducible urticarias (physical, cholinergic and other
types), angio-oedema without weals and urticarial vascu-
litis were excluded. The global response to ciclosporin
was designated as complete, partial or none based on
the assessment made by their attending clinician. The
time to respond to ciclosporin was also noted when this
information could be gleaned from the notes. The time
to onset of a complete or partial response was cate-
gorised as immediate (within days), early (within a
month), late (from 1-3 months) and delayed (beyond 3
months). An increase in autoantibodies to thyroid per-
oxidase, thyroglobulin or both above the laboratory nor-
mal ranges was noted. Frequency associations were
analysed by the χ2 test (with Yates’s correction applied
for small numbers) and a probability of P<0.05 was con-
sidered significant.
For the BHRA, donor cells were obtained from blood
bank buffy coat cells fulfilling the following criteria for
optimal response: 1) anti-IgE induced histamine release >
30%; 2) a pool of 10 sera from healthy non atopic indivi-
duals releasing < 16.5% were included as negative con-
trols and 3) pools of 10 positive sera being either low
positive (20 – 25%), moderate positive (30 – 35%) ord. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 2 Time from starting ciclosporin to observing a
clinical response in CSU patients with positive and
negative serum BHRA
+ve BHRA -ve BHRA
Immediate (days) 5 (25%) 0 (0%)
Early (< 1 month) 12 (48%) 11 (69%)
Late (1-3 months) 8 (32%) 4 (25%)
Delayed (> 3 months) 0 (0%) 1 (6%)
χ2 = 5.7, df = 3, P<0.1.
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controls.
A diagnosis of CSU (with or without angio-oedema)
was made in 398 patients. The BHRA was positive in
105 (26.4%). Fifty eight patients who were unresponsive
to second generation H1 antihistamines at up to fourfold
licensed doses, with or without montelukast, were trea-
ted with ciclosporin (14.6% of the total). The BHRA was
positive prior to treatment in 27 and negative in 31
patients. Three of the BHRA-positive patients and four
of the BHRA-negative patients were on prednisolone
(dose range 5-30 mg daily) at the time of starting ciclos-
porin without satisfactory disease control. None of them
had received prior treatment with immunosuppressive
therapies, including methotrexate or mycophenolate
mofetil.
Their response to ciclosporin is summarized in Table 1.
Eighty one percent of the BHRA+patients responded
completely to ciclosporin but only 19% of the BHRA-
patients did so (P<0.001). There was a trend to an earlier
response in BHRA+patients that was not significant
(Table 2). A positive serum BHRA was associated with
increased thyroid autoantibodies (P<0.02, Table 3).
The results of this retrospective case record review
confirm the earlier findings of a double-blind placebo
controlled study of ciclosporin [5] in which 13 of 18
clinical responders but only 1 of 9 non-responders to
ciclosporin had a positive BHRA (p<0.01) but in a larger
number of CU patients. They also confirm the findings
of Kikuchi et al. [4] who found that there was a positive
association between antithyroid antibodies in the sera of
CSU patients with whole serum induced histamine re-
leasing activity on heterologous basophils. The data on
timing of response to ciclosporin is not strong enough
to reach statistical significance but is in keeping with the
clinical impression that most patients with a positive
BHRA not only respond completely but often very
rapidly.
The practical importance of these observations is that
the BHRA can be used to predict a complete response to
ciclosporin in patients with antihistamine-unresponsive
CSU and justify the risks of using it as a short-term third-
line therapy. Furthermore the good response to ciclosporin
seen in patients with a positive BHRA and the association
with thyroid autoimmunity provide further support for theTable 1 Clinical response to ciclosporin in CSU patients
with positive and negative serum BHRA
+ve BHRA -ve BHRA
Complete response 22 (81%) 6 (19%)
Partial response 3 (11%) 10 (32%)
No response 2 (8%) 15 (49%)
χ2 = 22.7, df = 2, P<0.001.concept of autoimmune urticaria in a subset of patients
with the ordinary presentation of CSU [7]. The partial re-
sponse seen in 10/31 (32%) of patients with a negative
BHRA is probably due to temporary stabilization of hista-
mine release from mast cells and basophils during treat-
ment only. By contrast, the complete disease clearance in
81% of the CSU patients with a positive BHRA as a marker
of functional IgG autoantibodies would be in keeping with
the reduction of serum histamine releasing activity seen
within one month of starting ciclosporin [5] in addition to
any direct inhibitory effect on mast cell histamine release.
There was insufficient detail in the electronic patient
records to draw conclusions about the severity of CU
with or without a positive BHRA or the degree of re-
sponsiveness of patients to H1 antihistamines before
treatment with ciclosporin and this would be worth
examining in any future prospective study. The propor-
tion of CSU patients requiring ciclosporin is very similar
to the proportion of patients who were antihistamine-
resistant in another recent large series from Italy (13.6%)
[8]. Forty seven percent of these responded well to a 10-
day reducing course of prednisolone with subsequent
satisfactory control of their disease with antihistamines
alone and the remainder were treated with ciclosporin.
It is unknown whether or not the oral steroids pre-
scribed to the seven patients in our series influenced the
subsequent response to ciclosporin. Even if accurate in-
formation had been available, the numbers of BHRA
positive and negative patients would have been too small
to draw any meaningful conclusions.
The main limitations of this study are the retrospective
data collection and the extraction of relevant informa-
tion relating to the time to clinical response from the
clinic letters. The researcher involved in collecting the
clinical data from the patients’ electronic patient records
(KI) was not involved with the care of any of the patientsTable 3 Frequency association of thyroid antibodies in
CSU patients with positive and negative serum BHRA
+ve BHRA -ve BHRA
+ve thyroid antibodies 9 (37%) 1 (4%)
-ve thyroid antibodies 15 (63%) 21 (96%)
χY
2 = 5.52, df = 1, P<0.02.
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wards a particular outcome. The proportion of CU
patients with a positive BHRA on the HR-UrtikariaW test
is similar to a much larger series from patients with
CSU sent to RefLab for testing by clinicians in different
countries across Europe [6].
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